Subcutaneous Insulin Selection for Glycemic Control
Recommended Insulin Regimen Structure
- The American Diabetes Association recommends a basal-bolus regimen for comprehensive glycemic control, consisting of basal insulin and prandial (bolus) insulin, with correction insulin as needed 1, 2
- Basal insulin provides background insulin coverage throughout the day, while prandial insulin is administered immediately before each meal 1, 2
- This regimen significantly improves glycemic control and reduces hospital complications compared to sliding scale insulin alone 1
Specific Insulin Types and Their Uses
- Rapid-acting insulin analogs, such as insulin lispro, aspart, or glulisine, are recommended for prandial coverage, providing better postprandial glucose control compared to regular human insulin 3
- NPH insulin or long-acting analogs, such as glargine, detemir, or degludec, are used for basal insulin coverage, with similar glycemic control in hospital settings 1, 4
Special Clinical Scenarios
- For patients with poor or no oral intake, basal insulin alone or basal plus correction insulin is recommended, rather than prandial doses 1, 2
- For continuous tube feeding, NPH insulin administered every 8-12 hours is recommended, with correctional rapid-acting insulin every 4-6 hours as needed 4
- For insulin pump therapy, rapid-acting insulin analogs are the preferred choice, providing superior postprandial control compared to regular insulin 3, 5, 6
Transitioning from IV to Subcutaneous Insulin
- Subcutaneous basal insulin should be administered 2-4 hours before discontinuing IV insulin, with a conversion dose of 60-80% of total daily IV insulin 1, 2
Critical Pitfalls to Avoid
- Sliding scale insulin alone is strongly discouraged in hospitalized patients, as it leads to poor glycemic control 1, 2
- Inadequate monitoring after dose changes can lead to hypo- or hyperglycemia, and blood glucose should be monitored every 4-6 hours after any insulin adjustment 4